(Q37830362)

24 August 2017

1 reference

title

Improving cancer immunotherapy by targeting tumor-induced immune suppression (English)

1 reference

24 August 2017

1 reference

Mark J Smyth

2

0 references

author name string

Trina J Stewart

series ordinal

1

1 reference

24 August 2017

publication date

1 March 2011

1 reference

Cancer and Metastasis Reviews

24 August 2017

published in

1 reference

24 August 2017

volume

30

1 reference

24 August 2017

issue

1

1 reference

24 August 2017

page(s)

125-140

1 reference

https://scigraph.springernature.com/pub.10.1007/s10555-011-9280-5

24 August 2017

exact match

0 references

cites work

Immunological responses can have both pro- and antitumour effects: implications for immunotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Tumor antigen-specific T helper cells in cancer immunity and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

The immunobiology of cancer immunosurveillance and immunoediting

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Immune surveillance of tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

How tumours escape mass destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Cellular therapy to control tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Adoptive cell therapy for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Properties and origin of human Th17 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Myeloid-derived suppressor cells as regulators of the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Altered macrophage differentiation and immune dysfunction in tumor development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Derangement of immune responses by myeloid suppressor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Interleukin-10 and the interleukin-10 receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

L-Arginine modulates CD3zeta expression and T cell function in activated human T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Inhibition of tumor growth by elimination of granulocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Modulating the expression of IFN regulatory factor 8 alters the protumorigenic behavior of CD11b+Gr-1+ myeloid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Interferon regulatory factor-8 modulates the development of tumour-induced CD11b+Gr-1+ myeloid cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

NKT cells: facts, functions and fallacies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Raising the NKT cell family

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

NKT cells - conductors of tumor immunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Harnessing invariant NKT cells in vaccination strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Cross-regulation between type I and type II NKT cells in regulating tumor immunity: a new immunoregulatory axis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Immune suppression and skin cancer development: regulation by NKT cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

CD1d-restricted natural killer T cells can down-regulate tumor immunosurveillance independent of interleukin-4 receptor-signal transducer and activator of transcription 6 or transforming growth factor-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

A nonclassical non-Valpha14Jalpha18 CD1d-restricted (type II) NKT cell is sufficient for down-regulation of tumor immunosurveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Natural immunosurveillance against spontaneous, autochthonous breast cancers revealed and enhanced by blockade of IL-13-mediated negative regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Role of IL-13 in regulation of anti-tumor immunity and tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Cytokines in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Chemokine-chemokine receptors in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Transforming growth factor-beta in T-cell biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Regulation of immune responses by TGF-beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

TGF-beta: a master of all T cell trades

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

A role for endogenous transforming growth factor beta 1 in Langerhans cell biology: the skin of transforming growth factor beta 1 null mice is devoid of epidermal Langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Tumour microenvironment: TGFbeta: the molecular Jekyll and Hyde of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Synergistic enhancement of CD8+ T cell-mediated tumor vaccine efficacy by an anti-transforming growth factor-beta monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Systemic inhibition of transforming growth factor-beta in glioma-bearing mice improves the therapeutic efficacy of glioma-associated antigen peptide vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Treatment of malignant gliomas with TGF-beta2 antisense oligonucleotides

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Interleukin-10 in viral diseases and cancer: exiting the labyrinth?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

CCL2 (monocyte chemoattractant protein-1) and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Therapy for pneumonitis and sialadenitis by accumulation of CCR2-expressing CD4+CD25+ regulatory T cells in MRL/lpr mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Recombined CC chemokine ligand 2 into B16 cells induces production of Th2-dominant [correction of dominanted] cytokines and inhibits melanoma metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Preferential migration of regulatory T cells mediated by glioma-secreted chemokines can be blocked with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Tumour-educated macrophages promote tumour progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcino

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Signaling defects in anti-tumor T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

CTLA-4: new insights into its biological function and use in tumor immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

The clinical utility of cytotoxic T lymphocyte antigen 4 abrogation by human antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Role of B7-H1 and B7-H4 molecules in down-regulating effector phase of T-cell immunity: novel cancer escaping mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

PD1 blockade reverses the suppression of melanoma antigen-specific CTL by CD4+ CD25(Hi) regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Blockade of B7-H1 improves myeloid dendritic cell–mediated antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Amino acids and immune function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Regulation of immune responses by L-arginine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Nitric oxide, a double edged sword in cancer biology: searching for therapeutic opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

CD73-generated adenosine restricts lymphocyte migration into draining lymph nodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Indoleamine 2,3-dioxygenase, an emerging target for anti-cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Prevention of allogeneic fetal rejection by tryptophan catabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

CTLA-4-Ig regulates tryptophan catabolism in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Indoleamine 2,3-dioxygenase and tumor-induced tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Indoleamine 2,3-dioxygenase in immune suppression and cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Cyclooxygenases, prostanoids, and tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Back to the future: COX-2 inhibitors for chemoprevention and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Prostaglandins as modulators of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Targeting cyclooxygenase-2 in recurrent non-small cell lung cancer: a phase II trial of celecoxib and docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

Gemcitabine plus celecoxib (GECO) in advanced pancreatic cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10555-011-9280-5

10.1007/S10555-011-9280-5

21 January 2018

Identifiers

DOI

1 reference

release_4yknre42ujghflbi2yinkyxzm4

24 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4yknre42ujghflbi2yinkyxzm4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference